Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave

Market Focus07-15

On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.

The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \"inquiry received,\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.

The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \"1+6\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130433920?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130433920","market":"us","top_or_hot":-1,"title":"Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave","media":"Market Focus","content":"<p><p>On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.</p><p>The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.</p><p>The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜DotBio Rises 5.12% in Regular Trading, A-Share IPO Enters Inquiry Stage Amid HK-to-A Return Wave\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.</p><p>The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.</p><p>The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1130433920","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130433920","pubTimestamp":1784080068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.The rally comes amid sustained momentum from the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提醒|DotBio常规交易上涨5.12%，A股IPO在港股回归潮中进入询价阶段","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On July 15, DotBio-B (09606.HK) rose 5.12% in regular trading, trading at HK$233.4/share, with turnover of approximately HK$48.9 million.The rally comes amid sustained momentum from the company's A-share listing progress and supportive policy tailwinds. On July 3, the Shanghai Stock Exchange updated DotBio's STAR Market IPO review status to \\\"inquiry received,\\\" following the exchange's acceptance of the company's RMB-denominated share issuance application in mid-June. The prospectus indicates a planned fundraising of RMB 4.1 billion, earmarked entirely for new drug R&D projects. DotBio previously passed the CSRC Shanghai Bureau's guidance verification for its proposed STAR Market listing.The move also aligns with a broader wave of over 10 Hong Kong-listed technology and biotech firms pursuing A-share listings this year, supported by the STAR Market \\\"1+6\\\" reform and expanded inclusivity for unprofitable enterprises. Additionally, Dongwu Securities recently initiated coverage on DotBio with a Buy rating and a target price of HK$418.61, citing the company's leading ADC pipeline and global commercialization potential through its BioNTech partnership.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130433920","isCrawlerRequest":true}